SCHEMBL1992401

SCHEMBL1992401

NC(=O)Cc1ccnc(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.40
KMT2A Q03164 1/20 0.36
FFAR1 O14842 1/20 0.35
HTT P42858 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
CA2 P00918 1/20 0.34
LMNA P02545 1/20 0.34
MAP4K4 O95819 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27850220 0.83 FFAR1 (0.42) FFAR1CA2LMNAGABRPGABRD
SCHEMBL26096642 0.81 FFAR1 (0.35) FFAR1NPC1RAB9A
SCHEMBL28223050 0.78 HTT (0.43) IDH1KMT2AHTTCA2RAB9A
SCHEMBL28609201 0.77 AOC3 (0.36) FFAR1LMNAMAP4K4NPC1RAB9A
SCHEMBL17618001 0.77 ALDH1A1 (0.45) KMT2ANPC1RAB9A
SCHEMBL31264104 0.77 MRGPRX4 (0.33) IDH1NPC1RAB9A
SCHEMBL24760727 0.76 RAB9A (0.53) KMT2ANPC1RAB9ACYP3A4CYP2C19
SCHEMBL3252516 0.76 RAB9A (0.60) KMT2AMAP4K4NPC1RAB9A
SCHEMBL29107106 0.75 LMNA (0.38) FFAR1CA2LMNAMAP4K4CYP2C19
SCHEMBL10175014 0.75 MAPT (0.46) KMT2ALMNARAB9ACYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3883925-A1 CYCLIC UREAS Sironax Ltd (KY) 2021-09-29 EP disclosed
CN-106573934-B The inhibition of transient receptor potential A1 ion channel 伊莱利利公司 2019-10-11 CN disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
EP-1675830-A4 HETEROCYCLIC AMIDES AND SULFONAMIDES SCIOS INC (US) 2008-08-20 EP disclosed
US-20060199821-A1 Heterocyclic amides and sulfonamides SCIOS, INC. (US) 2006-09-07 US disclosed
EP-1675830-A2 HETEROCYCLIC AMIDES AND SULFONAMIDES SCIOS INC. (US) 2006-07-05 EP disclosed
WO-2005033072-A2 HETEROCYCLIC AMIDES AND SULFONAMIDES SCIOS INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO IDH1 649/4885KMT2A 3648/4885FFAR1 3226/4885
US-20060199821-A1 Heterocyclic amides and sulfonamides MAP4K2, MAP3K8, MAP3K2 IDH1 989/4885KMT2A 805/4885FFAR1 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.